An association between treatment adherence in Alzheimer disease and improved QoL for persons with dementia is claimed in a nonsystematic review of literature on factors affecting adherence to cholinesterase inhibitors, the main class of therapeutic drugs [35]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.